Home Companies Catalysts Deep Dives
Jardiance empagliflozin APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2014-08-01
US LOE2025-01-01
Peak Sales Est$10000M
Formulations[{"id":"jardiance-oral","doses":"10mg, 25mg","route":"ORAL","setting":"PATIENT_SELF","duration":"Chr
Companies
LLY (CO_DEVELOPER)50%
BI (CO_DEVELOPER)50%
Mechanism: SGLT2 inhibitor
Expert: Sodium-glucose co-transporter 2 inhibitor that reduces glucose reabsorption in proximal tubule; cardioprotective effects via hemodynamic, metabolic, and anti-inflammatory mechanisms.
Everyday: Helps the body remove excess sugar through urine, also protects the heart and kidneys.
Targets: ["SGLT2"]
Revenue History
PeriodRevenue ($M)
Q3 2024$800M
2024$3,000M
Programs (3)
IndicationStageKey StudyRegional Status
CKDAPPROVEDEMPA-KIDNEY[{"stage":"APPROVED","region":"US","approval_date":"2023-06-22"},{"stage":"APPRO
HFrEF/HFpEFAPPROVEDEMPEROR-Reduced/Preserved[{"stage":"APPROVED","region":"US","label_notes":"HFrEF; HFpEF added Feb 2022","
T2DAPPROVEDEMPA-REG OUTCOME[{"stage":"APPROVED","region":"US","approval_date":"2014-08-01"},{"stage":"APPRO
Notes
First SGLT2 to show CV mortality benefit (EMPA-REG). Also approved for HFrEF, HFpEF, CKD.
Data from Supabase · Updated 2026-03-24